MAPT and Alzheimer disease: However, at least 40% of cognitively normal elderly patients show amyloid or tau pathology, indicating that these molecular biomarkers are not sufficient to distinguish healthy aging from AD-induced cognitive decline (Boyle et al., 2013; Caselli and Reiman, 2013).